Navigation Links
Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
Date:7/17/2012

EAST BRUNSWICK, N.J., July 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's second quarter 2012 financial results will be released prior to the market open on Wednesday, August 8, 2012.  Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on August 8, 2012 to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99954484.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.
A telephone replay will be available for fourteen days by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99954484.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.  

SVNT-IContact: Mary Coleman 

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
2. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
5. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
6. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
7. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
8. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
9. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
10. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
11. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... Linda, Ca (PRWEB) , ... June 20, 2017 ... ... of alternative polyA sites. To understand their regulatory principles, the research team developed ... mRNA-Seq, iCLIP and RNA motif analyses. This reveals at nucleotide resolution the ‘RNA ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... , ... June 20, 2017 , ... The law firm ... on his installation as the president of the DuPage County Bar Association’s Board of ... Installation Dinner June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC ...
Breaking Medicine News(10 mins):